Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Mirum Pharmaceuticals, Inc. < Previous 1 2 3 4 5 Next > Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older December 13, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 09, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Provides Development Program Updates November 29, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences November 18, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update November 09, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD November 07, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022 November 01, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases October 31, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) October 24, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics October 18, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older October 14, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting October 12, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting October 05, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 12, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences August 30, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock August 12, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 10, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock August 09, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock August 09, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update August 04, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 July 28, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 08, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting June 24, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL) June 24, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses June 13, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors June 06, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals May 23, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences May 18, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.